• SB 431542: Potent ALK5 Inhibitor for TGF-β Pathway Research

  2026-06-12

  SB 431542 is a highly selective ALK5 inhibitor employed to block TGF-β signaling in cellular and immunological studies. It exhibits >100-fold selectivity versus non-TGF-β kinases and robustly inhibits Smad2 phosphorylation, making it a reliable tool for dissecting TGF-β pathway function.

• NBC19: Redefining NLRP3 Inflammasome Inhibition in Sepsis Re

  2026-06-12

  NBC19, a nanomolar NLRP3 inflammasome inhibitor from APExBIO, is transforming translational inflammation research. This thought-leadership piece connects recent discoveries in lactate-driven HMGB1 release to the strategic use of NBC19 in experimental models. By integrating mechanistic insight, evidence from sepsis studies, and advanced guidance for protocol design, we chart a new path for translational scientists seeking robust, clinically relevant data.

• Enhancing Cannabinoid Signaling Assays with Tetrahydromagnol

  2026-06-11

  Tetrahydromagnolol (SKU C5552) is a highly selective peripheral CB2 receptor agonist that enables precise, reproducible data in cannabinoid receptor research and anti-inflammatory assays. This article uses real experimental scenarios to demonstrate how SKU C5552 addresses common lab challenges in viability and cytotoxicity workflows.

• Epacadostat (INCB024360): IDO1 Inhibition in Immuno-Oncology

  2026-06-11

  Epacadostat (INCB024360) is a selective, orally active IDO1 inhibitor that disrupts tumor-mediated immune suppression. It exhibits nanomolar potency in both recombinant and cellular assays, supporting its use in immuno-oncology research and combination immunotherapies. The compound’s robust solubility profile and validated protocol parameters make it a reliable tool for dissecting immune metabolism and T cell restoration.

• NF 340: P2Y11 Antagonist for Advanced GPCR Signaling Researc

  2026-06-10

  NF 340 is a potent and selective P2Y11 antagonist that empowers researchers to dissect complex GPCR signaling in cancer metastasis and immunology. Its validated specificity, reproducible performance, and protocol flexibility make it a standout choice for studies targeting purinergic receptor pathways and inflammation.

• SB 431542: ALK5 Inhibitor Workflows for TGF-β Pathway Dissec

  2026-06-10

  SB 431542, a potent ALK5 inhibitor, is revolutionizing TGF-β pathway studies by enabling precise, reproducible control over cellular and immunological assays. This article outlines best practices for experimental design, troubleshooting, and leveraging the latest insights from cryoablation immunology research.

• Phenothiazines Enhance Macrophage Antibacterial Activity via

  2026-06-09

  Qiu et al. (2025) demonstrate that phenothiazines, including promethazine hydrochloride, significantly augment the antibacterial action of macrophages by inducing reactive oxygen species (ROS) production and autophagy. This mechanism highlights a promising, resistance-sparing host-directed strategy for combating intracellular bacterial infections.

• Promethazine HCl in Immunology: Protocols & Advanced Applica

  2026-06-09

  Promethazine hydrochloride is redefining host defense research through its robust induction of ROS and autophagy pathways in macrophages, offering a host-directed route to tackle antibiotic-resistant infections. This guide details actionable workflows, troubleshooting strategies, and experimental insights leveraging high-purity Promethazine HCl from APExBIO for reproducible immunology and inflammation studies.

• Direct Mouse Genotyping Kit: Rapid PCR from Mouse Tissue

  2026-06-08

  The Direct Mouse Genotyping Kit enables fast, convenient PCR-based genotyping directly from mouse tissue samples, eliminating the need for traditional DNA purification. It is best suited for high-throughput genotyping and routine genetic screening in biomedical research, but should not be used when ultra-pure DNA is required for downstream applications beyond PCR.

• Ribonuclease R (RNase R) (20 U/μL): Precision in Circular RN

  2026-06-08

  Ribonuclease R (RNase R) (20 U/μL) is an exoribonuclease that selectively digests linear RNA, enabling robust enrichment of circular RNAs for structure-function and stability studies. Its specificity and processivity make it a benchmark tool for dissecting RNA processing pathways, as validated by recent research on circRNA roles in cancer and inflammation.

• SB 431542: Precision ALK5 Inhibition in Primary Trophoblast-

  2026-06-07

  Explore how SB 431542, a potent ALK5 inhibitor, uniquely enables high-fidelity studies of TGF-β signaling in primary trophoblast-immune cell co-cultures. Discover protocol guidance and scientific context not covered in standard organoid or cell line-based research.

• Tofacitinib (CP-690550): Mechanistic Advances in RA Macropha

  2026-06-06

  Tofacitinib (CP-690550) is redefining translational strategies in rheumatoid arthritis by uniquely reversing both inflammatory and mitochondrial defects in GM-CSF-reprogrammed macrophages. This article synthesizes mechanistic insights, recent experimental breakthroughs, and evidence-based protocol guidance—offering translational researchers a strategic roadmap for leveraging targeted JAK inhibition in immune modulation research.

• ERK Inhibition Reduces Mitochondrial Fragmentation and Autop

  2026-06-05

  Yuan et al. (2023) elucidate how ERK inhibition mitigates mitochondrial fragmentation and excessive autophagy to protect neuronal cells from oxygen-glucose deprivation/reoxygenation injury—a model of cerebral ischemia-reperfusion. These findings clarify the ERK–Drp1/Mfn2–autophagy axis in neuroprotection and offer mechanistic insights relevant for translational stroke research.

• Radicicol: Hsp90 Inhibitor Workflows for Apoptosis & Inflamm

  2026-06-05

  Radicicol, a potent Hsp90 inhibitor, streamlines research into apoptosis, adipogenesis, and sepsis inflammation. Explore advanced workflows, troubleshooting insights, and unique cross-applications that set Radicicol apart as an essential tool for translational cell signaling research.

• CLEC5A and ISG20 Drive Atherosclerosis: Causal Evidence and

  2026-06-04

  Zhang et al. (2025) rigorously demonstrate that CLEC5A and ISG20 are causal drivers of atherosclerosis using integrated Mendelian randomization (MR), eQTL analysis, and functional assays. Their work not only clarifies the molecular mechanisms by which ISG20 promotes plaque progression, but also provides a robust framework for experimental validation in immunological and cardiovascular research.

510 records 12/34 page Previous Next First page 上5页 1112131415 下5页 Last page